SH3 domain and tetratricopeptide repeats 1Genealiases: []
Q-omics provides the consensus-scored SH3TC1 profile across patient tissues and cancer cell-line models. SH3TC1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SH3TC1 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, SH3TC1 protein abundance shows 20,416 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRP, and LSCC as cancer lineages where SH3TC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH3TC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH3TC1 survival associations across molecular data types. SH3TC1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH3TC1 RNA expression–survival associations across cancer types. High SH3TC1 expression shows unfavorable associations in MESO, LUSC, LGG and LAML, but favorable associations in KIRC and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SH3TC1 RNA expression.
This table summarizes SH3TC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SH3TC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH3TC1 shows lower tumor expression in KIRP and THCA and higher tumor expression in COAD, HNSC, STAD and BRCA. The KIRP box plot shows higher SH3TC1 RNA expression in normal versus tumor tissue (log2 FC = −1.325, t-test p < 0.001).
This table shows molecular features associated with SH3TC1 in patient tissues and cancer cell lines. In patient samples, SH3TC1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SH3TC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
